The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients
Abstract
Late-onset Pompe's disease (acid maltase deficiency, glycogen storage disease type II) is a slowly progressive myopathy caused by deficiency of acid alpha-glucosidase. Current developments in enzyme replacement therapy require detailed knowledge of the kind and severity of symptoms and the natural course of the disease in the patient population. A detailed questionnaire covering the patients' medical history and current situation was developed and information was gathered from 54 Dutch patients. The mean age of the participants was 48.6 +/- 15.6 years. The first complaints started at a mean age of 28.1 +/- 14.3 years and were mostly related to mobility problems and limb-girdle weakness. Fifty-eight percent of the adult patients indicated the presence of mild muscular symptoms during childhood. Twenty-eight percent of the patients waited >5 years for the final diagnosis after the first visit to a physician for disease-related complaints. At the time of questionnaire completion, 48% of the study population used a wheelchair and 37% used artificial ventilation. Movements such as rising from an armchair, taking stairs or getting upright after bending over were difficult or impossible for more than two-thirds of the respondents. The age at onset, the rate of disease progression and the sequence of respiratory and skeletal muscle involvement varied substantially between patients. Seventy-six percent of the participants indicated being troubled by fatigue and 46% by pain. This survey has mapped the age at onset, presenting symptoms, heterogeneity in progression and range of disease severity in a large group of Dutch patients. We conclude that early manifestations in childhood require proper attention to prevent unnecessary delay of the diagnosis. The follow-up of patients with late-onset Pompe's disease should focus on respiratory and limb-girdle muscle function, the capacity to perform daily activities, and the presentation of fatigue and pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172
Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
van den Hout, H. M. P., Hop, W., van Diggelen, O. P., Smeitink, J. A. M., Smit, G. P. A., Poll-The, B.-T. T., Bakker, H. D., Loonen, M. C. B., de Klerk, J. B. C., Reuser, A. J. J., et al. (2003) · Pediatrics · doi:10.1542/peds.112.2.332 · Cited by 555
Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human α-Glucosidase From Milk
Van den Hout, J. M. P., Kamphoven, J. H. J., Winkel, L. P. F., Arts, W. F. M., Klerk, J. B. C. D., Loonen, M. C. B., Vulto, A. G., Cromme-Dijkhuis, A., Weisglas-Kuperus, N., Hop, W., et al. (2004) · Pediatrics · doi:10.1542/peds.113.5.e448 · Cited by 355
Recombinant human α-glucosidase from rabbit milk in Pompe patients
Van den Hout, H., Reuser, A. J., Vulto, A. G., Christa B Loonen, M., Cromme-Dijkhuis, A., & Van der Ploeg, A. T. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02533-2 · Cited by 330
Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies
Merkies, I. S. J. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.5.596 · Cited by 311
Ausems, M., Verbiest, J., Hermans, M., Kroos, M., Beemer, F., Wokke, J., Sandkuijl, L., Reuser, A., & van der Ploeg, A. (1999) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200367 · Cited by 307
Fatigue in immune-mediated polyneuropathies
Merkies, I. S. J., Schmitz, P. I. M., Samijn, J. P. A., van der Meché, F. G. A., & van Doorn, P. A. (1999) · Neurology · doi:10.1212/wnl.53.8.1648 · Cited by 277
Pompe disease in infants and children
Kishnani, P. S., & Howell, R. R. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.01.053 · Cited by 267
Enzyme replacement therapy in late‐onset Pompe's disease: A three‐year follow‐up
Winkel, L. P. F., Van den Hout, J. M. P., Kamphoven, J. H. J., Disseldorp, J. A. M., Remmerswaal, M., Arts, W. F. M., Loonen, M. C. B., Vulto, A. G., Van Doorn, P. A., De Jong, G., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20019 · Cited by 233
Cited by
van der Ploeg, A. T., & Reuser, A. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61555-x · Cited by 756
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
van der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., Herson, S., Kishnani, P. S., Laforet, P., Lake, S. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909859 · Cited by 745
Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease
Fukuda, T., Ewan, L., Bauer, M., Mattaliano, R. J., Zaal, K., Ralston, E., Plotz, P. H., & Raben, N. (2006) · Annals of Neurology · doi:10.1002/ana.20807 · Cited by 303
Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132
Exercise is muscle mitochondrial medicine
Oliveira, A. N., Richards, B. J., Slavin, M., & Hood, D. A. (2021) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000250 · Cited by 26
Metadata
- Authors
- Hagemans, M. L. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-05
- Volume
- 128
- Issue
- 3
- Pages
- 671-677
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2145986851
- Cited by
- 364
- References
- 16
- FWCI
- 9.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.